Global Complete Androgen Insensitivity Syndrome Market – Industry Trends and Forecast to 2029

Market Analysis and Size                              

Androgen Insensitivity Syndrome (AIS) is an inherited genetic condition that affects around one out of every 20,000 persons. Complete androgen insensitivity syndrome makes it impossible for the body's cells to respond to androgen, or male hormones.  Some persons are androgen insensitive to some extent. Complete androgen insensitivity syndrome impacts sexual development before and after birth, as well as during puberty. This disorder affects people who are genetically male (one X and one Y chromosome) but do not respond to male hormones. As a result, their external genitalia and breasts are typically female. They lack a uterus or cervix, hence they are unable to menstruate or have children.

Data Bridge Market Research analyses that the complete androgen insensitivity syndrome? market was valued at USD 491.43 million in 2021 and is expected to reach USD 726.07 million by 2029, registering a CAGR of 5.0% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Complete androgen insensitivity syndrome (CAIS) is a genetic disorder in which a child is genetically male but has female sex traits. CAIS is a sex development condition (DSD). The testes are removed either after puberty when feminization is complete or before puberty, and estrogen treatment is administered at puberty. To avoid dyspareunia, vaginal dilation may be recommended. Bone mineral density scans are required every five years for adults. Disclosure necessitates psychological assistance.

Complete Androgen Insensitivity Syndrome Market Dynamics

Drivers

• Rise in the number of cases of complete androgen insensitivity syndrome?

The surging number of complete androgen insensitivity syndrome? cases is anticipated to be a major factor driving the market's growth rate during the forecast period of 2022-2029. Males who inherit a faulty gene from their mothers, known as the androgen receptor (AR) gene, have a 1 in 4 chance of having androgen insensitivity syndrome (AIS). Females can inherit the gene and carry it, but they will not develop AIS. Complete androgen insensitivity syndrome is caused by a defective X-linked gene, which means it is a gene on the X chromosome that is passed down from mother to kid. This gene does not produce androgen receptors. These are the cells that help your body respond to androgens including testosterone.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of the complete androgen insensitivity syndrome? market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aim to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising government initiatives to spread awareness and sedentary lifestyle of people will result in the expansion of the complete androgen insensitivity syndrome? market. Along with this, favourable reimbursement policies and rising adoption of early diagnostic among people will enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the complete androgen insensitivity syndrome? market growth.

Moreover, the market's growth is fueled by rising technological advancement in diagnostic methods and emerging new markets. These factors will provide beneficial opportunities for the complete androgen insensitivity syndrome? market growth.

Restraints/Challenges

On the other hand, the high cost associated with the treatment and diagnosis will obstruct the growth rate of the market. The lack of healthcare infrastructure in developing economies and the dearth of skilled professionals will challenge the market's complete androgen insensitivity syndrome. Additionally, lack of awareness among people and unfavorable healthcare policies will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This complete androgen insensitivity syndrome? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the complete androgen insensitivity syndrome? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Androgen insensitivity is a rare condition. Partial androgen insensitivity syndrome affects about 1 in 99,000 male infants, while complete androgen insensitivity syndrome impact 2 to 5 per 100,000.

Complete androgen insensitivity syndrome? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Global Complete Androgen Insensitivity Syndrome Market Scope

The complete androgen insensitivity syndrome? market is segmented on the basis of symptoms, diagnosis, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Symptoms

• Abnormally Tall Stature
• Little or No Pubic Hair
• Shallow Vagina
• Undescended Testicles
• Amenorrhea
• Others

Diagnosis

• Blood Test
• Genetic Testing
• Pelvic Ultrasound
• Others

Treatment

• Surgery
• Estrogen Replacement Therapy
• Genetic Counselling
• Hormone Medications
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Complete Androgen Insensitivity Syndrome Market Regional Analysis/Insights

The complete androgen insensitivity syndrome? market is analysed and market size insights and trends are provided by country, symptoms, diagnosis, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the complete androgen insensitivity syndrome? market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the complete androgen insensitivity syndrome? market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing prevalence of androgen insensitivity syndrome? , and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, the growing presence of major key players will further propel the market's growth rate in this region.

Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the development of healthcare infrastructure in this region. Also, rising government initiatives will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Complete Androgen Insensitivity Syndrome Market Share Analysis

The complete androgen insensitivity syndrome? market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to complete androgen insensitivity syndrome? market.

Some of the major players operating in the complete androgen insensitivity syndrome? market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Eli Lilly and Company (U.S.)
• Merck & Co., Inc. (U.S.)
• Allergan (Ireland)
• Abbott (U.S.)
• Merck KGaA (Germany)
• Novo Nordisk A/S (Denmark)
• Genentech Inc. (U.S.)
• Amgen Inc. (U.S.)
• Endo International plc (Ireland)
• Hisamitsu Pharmaceutical Co.,Inc. (Japan)

SKU-68494